Company Overview: Mateon Therapeutics

Industry News

6 Sep

Mateon Therapeutics to Present at the 19th Annual Rodman and Renshaw Global Investment Conference on September 12, 2017

SOUTH SAN FRANCISCO, Calif., Sept. 06, 2017 (GLOBE NEWSWIRE) — Mateon Therapeutics, Inc. (MATN), a biopharmaceutical company developing vascular disrupting agents for the treatment of orphan oncology indications, today announced it will be featured as a presenting company at the 19th Annual Rodman & Renshaw Global Investment Conference. Mateon’s presentation...

Read more

16 Aug

Mateon Therapeutics Announces Results from Second Interim Analysis of CA4P Phase 2/3 FOCUS Study in Platinum-resistant Ovarian Cancer

Primary Endpoint – Early Progression Free Survival data favors CA4P CA4P continues to be safe and well-tolerated Next interim analysis expected in September SOUTH SAN FRANCISCO, Calif., Aug. 16, 2017 (GLOBE NEWSWIRE) — Mateon Therapeutics, Inc. (MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of...

Read more

1 Aug

Mateon Therapeutics Completes Enrollment in Phase 2 Portion of FOCUS Study of CA4P for Platinum-Resistant Ovarian Cancer

Recruitment rate significantly increased following initial positive interim analysis Interim data read-outs expected in August (40 patients), September (60 patients) and November (80 patients) SOUTH SAN FRANCISCO, Calif., Aug. 01, 2017 (GLOBE NEWSWIRE) — Mateon Therapeutics, Inc. (MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment...

Read more

31 Jul

Mateon Therapeutics Announces Positive Initial Data from Fifth Cohort of Phase 1b Study of OXi4503 in Relapsed/Refractory AML

Two patients of four (50%) achieved a complete remission No dose-limiting toxicities observed SOUTH SAN FRANCISCO, Calif., July 31, 2017 (GLOBE NEWSWIRE) — Mateon Therapeutics, Inc. (MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced preliminary data from the fifth dose...

Read more

28 Jun

Mateon Therapeutics Announces New Interim Preclinical Data on CA4P in Combination with Checkpoint Inhibitors

CA4P in combination with anti-CTLA-4 antibodies resulted in 77% reduction in tumor size compared to anti-CTLA-4 antibodies alone and 89% reduction compared to control Survival benefit observed for animals receiving combination therapy SOUTH SAN FRANCISCO, Calif., June 28, 2017 (GLOBE NEWSWIRE) — Mateon Therapeutics, Inc. (MATN), a biopharmaceutical company...

Read more

12 Jun

Mateon Therapeutics Provides Update on its Clinical Trial Programs and Milestones

SOUTH SAN FRANCISCO, Calif., June 12, 2017 (GLOBE NEWSWIRE) — Mateon Therapeutics, Inc. (MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today provided an update regarding the current status of all clinical trials of its investigational drugs. Company-sponsored studies: FOCUS for...

Read more

9 May

Mateon Provides Corporate Update and Reports First Quarter 2017 Financial Results

SOUTH SAN FRANCISCO, Calif., May 08, 2017 (GLOBE NEWSWIRE) — Mateon Therapeutics, Inc. (MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today provided a corporate update and reported financial results for the three months ended March 31, 2017. Recent Corporate Highlights...

Read more

27 Apr

Mateon Therapeutics Announces Presentations at the Tumor Microenvironment Workshop

SOUTH SAN FRANCISCO, Calif., April 27, 2017 (GLOBE NEWSWIRE) — Mateon Therapeutics, Inc. (MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced that four presentations regarding the company’s preclinical drug development programs will be presented at the Tumor Microenvironment Workshop...

Read more

20 Apr

Mateon Announces Initiation of Investigator-Sponsored Phase 1 Study of CA4P in Combination with Everolimus in Neuroendocrine Tumors

SOUTH SAN FRANCISCO, Calif., April 20, 2017 (GLOBE NEWSWIRE) — Mateon Therapeutics, Inc. (MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced that the Markey Cancer Center at the University of Kentucky has enrolled the first patient into a new...

Read more

Page 1 of 212

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address